+4,806.5%
MELI vs GSK
+137.8%
+4,668.7%
-89.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | -0.1% | +0.1% | 0.0% |
| 7D | -9.2% | -5.3% | -3.8% | -6.1% |
| 30D | -26.9% | -3.7% | -23.3% | -25.4% |
| 3M | -29.5% | -7.3% | -22.2% | -26.5% |
| 6M | -17.9% | -4.2% | -13.7% | -16.9% |
| YTD | -32.7% | +0.9% | -33.6% | -34.9% |
| 1Y | -28.7% | +7.3% | -36.0% | -33.7% |
| 3Y | -8.6% | +52.7% | -61.3% | -37.4% |
| 5Y | -3.3% | +40.1% | -43.4% | -31.5% |
| 10Y | +762.4% | +98.7% | +663.7% | +338.5% |
| All | +4,806.5% | +137.8% | +4,668.7% | +1,996.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling